//Transatlantic update and personal experience

Transatlantic update and personal experience

United States

Cases, + 102,004 = 27,229.862

Dearth, +3,589 = 474,423 (0.14% of population)

Hospitalizations, 69,283 (14,369, 4,643)

Vaccine doses since 14th December, 50, 641,884

First dose, 37,056,122

Booster doses, 13,082,172 (4.08%)

US COVID-19 Cases Caused by Variants

https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html

US B.1.1.7 dashboard

https://www.helix.com/pages/helix-covid-19-surveillance-dashboard

Florida
California
Georgia
Texas

CDC data

https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases

Past 7 days

https://www.washingtonpost.com/graphics/2020/national/coronavirus-us-cases-deaths/?itid=sf_coronavirus

New daily reported cases, down 22.1%

New daily reported deaths, down 5.8%

CoViD related hospitalizations, down 17.8%

Test positivity rate, 5.8%

https://covidtracking.com/data

United kingdom

UK data

Cases, + 13,308 = 4,027,106

Deaths, + 621 = 116,908 (0.18% of population)

Vaccinations

First dose, 14,556,827

Second dose, 534,869

https://coronavirus.data.gov.uk/details/cases

Tracker app data

https://covid.joinzoe.com/data#levels-over-time

Oxford University extends COVID-19 vaccine study to children

https://www.ovg.ox.ac.uk/news/oxford-university-extends-covid-19-vaccine-study-to-children

13th February

London, Southampton and Bristol

Safety and immune responses in children and young adults

Ages, 6 to 17 years

Single-blind, randomised phase II trial

N = 300 volunteers

Vaccine group, n = 240

Control group, n = 60, meningitis vaccine

Safe and gives a sore arm

Andrew Pollard

Professor of Paediatric Infection and Immunity, and Chief Investigator on the Oxford vaccine trial

While most children are relatively unaffected by coronavirus and are unlikely to become unwell with the infection,

it is important to establish the safety and immune response to the vaccine in children and young people as some children may benefit from vaccination.

These new trials will extend our understanding of control of SARS-CoV2 to younger age groups

Starting trials for younger children this spring

Pfizer

Moderna

Janssen